Fig. 1
Overexpression of SHARP1 in MLL-AF6 AML patients. a Venn diagram showing MLL-bound (101 genes) and H3K79me2 enriched genes (8904 genes) obtained from ChIP-seq analysis of ML-2 cells for identification of 92 MLL-AF6 target genes. b Volcano plot showing average log2 fold change against −log10 p value for all genes in MLL-AF6 AML (n = 14) vs all the other subtypes of MLL-rearranged AMLs (other MLLr) (n = 42). Gene expression data of patients were obtained from GSE19577, GSE14468 and GSE61804. Red dots MLL-AF6 target (92 genes), Green circles upregulated targets (9 genes), Black circles downregulated targets (8 genes). c Box plot showing SHARP1 log2 expression in AML patients and normal bone marrow (NBM) CD34 + cells. SHARP1 log2 expression level: MLL-AF6 7.504 ± 0.788 (n = 14), Other MLL 2.854 ± 0.065 (n = 42), Non-MLL 3.623 ± 0.064 (n = 276), NBM CD34 2.856 ± 0.036 (n = 12). Gene expression data of NBM CD34+ cells were from GSE19429. d, e Left panel: Unsupervised hierarchical gene-expression clustering from 2 distinct cohorts of adult AML patients from GSE1159 (d n = 285) and GSE6891 (e n = 268). The bars indicate SHARP1 gene expression. All of the five high SHARP1 cases have the MLL-AF6 fusion gene. Right panel: Box plot showing SHARP1 log2 expression in AML patients. SHARP1 log2 expression level: d MLL-AF6:10.45 ± 0.096 (n = 3), Other MLL 4.383 ± 0.082 (n = 15), Non-MLL 4.566 ± 0.045 (n = 258). The cytogenetics was not determined in 9 cases. e MLL-AF6 11.18 ± 0.828 (n = 2), Other MLL 5.916 ± 0.257 (n = 16), Non-MLL 5.658 ± 0.033 (n = 241). The cytogenetics was not determined in 9 cases. All box plots extend from the 25th to 75th percentiles and the whisker extends from the minimum level to the maximum. Median value is plotted in the box. ***p < 0.001
